NEW BRIGHTON, Minn.--(BUSINESS WIRE)--Regulatory News:
Cellectis (Paris:ALCLS) (NYSE PA: ALCLS), the global genome engineering specialist, announced the issuance by the USPTO on May 14th, 2013 of two new US patents (US 8,440,431 and US 8,440,432) directed to TAL-effector nucleases.
As a leader in the genome engineering industry, the molecules produced by Cellectis have been distributed to prestigious laboratories over the world under the trademark TALENTM. The technology provides to researchers tools and comprehensive solutions to edit genes efficiently in all cell types. TALENTM product represents the next generation gene-editing tool, it is an easy, fast and powerful technology for gene knock-out, knock-in and any targeted modifications of genomes. TALENTM product opens up whole new areas of life science research and therapeutics.
As early as 2011, the Cellectis Group has established a strong partnership with the University of Minnesota and the Iowa State University on this technology. Cellectis, which was the first company to industrialize the production and commercialize TAL-effector nucleases, is particularly active on the US market.
The inventors of both patents are Pr. Daniel Voytas, from the University of Minnesota, Dr. Adam Bogdanove from the Iowa State University and Dr. Feng Zhang who serves as Chief Operating Officer of Cellectis Plant Sciences in New Brighton (MN), a subsidiary dedicated to applying sequence-specific nucleases in plants for agricultural biotechnology applications. Pr. Daniel Voytas is also the Chief Scientific Officer of Cellectis Plant Sciences.
TALEN™ products are the next step technology of synthetic biology. Cellectis, which retains all exclusive rights on the patents owned by University of Minnesota and the Iowa State University, is able to provide to its clients efficient solutions to edit any gene in any cell type in 4 weeks: human, animal, algae, plant, as well as in viral and bacterial DNA.
Pr. Daniel Voytas said that “thanks to its technology, Cellectis develops easy and ready-to-use tools for genome customization enabling the engineering of cells with optimized features for drug discovery, gene function studies and industrial biotechnology.”
TALEN™ are commercialized through Cellectis bioresearch, the commercial subsidiary of Cellectis.
We are committed to provide the best-in-class support to our customers.
For further information please contact us: contact@cellectis-bioresearch.com
About Cellectis
Founded in 1999, the Cellectis Group runs on highly specific DNA engineering technologies. Its application sectors are human health, agriculture and bio-energies. Co-initiated by André Choulika, its Chairman and CEO, Cellectis is now one of the world’s leading companies in the field of genome engineering, with revenue of $27 million in 2012. Leading the field of pluripotent stem cells, Cellectis has developed expertise in drug discovery, the study of drug toxicity and regenerative medicine. Cellectis has a solid background in the large-scale handling of stem cells up until their maturation and differentiation into functional cell types. Cellectis has a workforce of 230 employees working at 5 sites worldwide: New Brighton (Minnesota) & Cambridge (Massachusetts) in the United States, Gothenburg in Sweden and Paris & Evry in France.
The Group has signed over 100 industry agreements with pharmaceutical, agrochemical, and biotechnology companies. University College London (UCL), the National Institute of Health (NIH), Novo Nordisk, the Center for iPS Cell Research and Application (CiRA) of Kyoto University, AFM, Novartis, BASF, Bayer and Limagrain are some of the Group’s clients and partners. Since 2007, Cellectis has been listed on the NYSE Euronext Alternext market (code: ALCLS) in Paris.
For more information, visit our website: www.cellectis.com.
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
